All patients underwent bone marrow aspiration for morphology and immunophenotyping diagnosis; CD56 is a unique marker found in 10% of APL cases and is associated with a poor prognosis, with a higher risk of relapse in adult patients [23]; in the current study, CD56 was detected in only 7 (11%) patients, with no significant P-value. Here, NCAM1 is linked to acute promyelocytic leukemia.